Otsuka Holdings Co., Ltd. (4578) Press Release
Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median PFS Benefit in Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation NSCLC
Earlier from Otsuka
- Zipalertinib Plus Chemotherapy Meets Primary PFS Endpoint in Planned Interim Analysis of Phase 3 REZILIENT3 Trial
- Otsuka Unveils Unprecedented Phase 3 VISIONARY Two-Year eGFR Results Demonstrating VOYXACT® (sibeprenlimab-szsi) Stabilizes Kidney Function Decline to Baseline Physiologic Rate, Fundamentally Altering Disease Progression in IgA Nephropathy (IgAN)
- Consolidated Financial Results for the Six-Month Period Ended June 30, 2026 [IFRS]
- Notice Regarding Revisions of Consolidated Results Forecast for the first half of FY2026